A Phase 2, Open-Label, Multi-Center Study of Safety, Tolerability, and Efficacy of AFN-12520000 in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Due to Staphylococci.

Trial Profile

A Phase 2, Open-Label, Multi-Center Study of Safety, Tolerability, and Efficacy of AFN-12520000 in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Due to Staphylococci.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Dec 2015

At a glance

  • Drugs Debio 1452 (Primary)
  • Indications Skin and soft tissue infections; Staphylococcal infections
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Affinium Pharmaceuticals
  • Most Recent Events

    • 28 Dec 2015 Results published in the Antimicrobial Agents and Chemotherapy
    • 13 Sep 2013 Results presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy.
    • 04 Sep 2013 Results will be presented at the 2013 Interscience Conference on Antimicrobial Agents & Chemotherapy (ICAAC-2013) according to an Affinium Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top